British Government declared This Friday (6), the United Kingdom’s Health Secretary Steve Barclay will seal a partnership with German pharmaceutical company BioNTech with the aim of developing a vaccine against cancer.
The deal gives cancer patients in the UK early access to research trials mRNA vaccines. This is the same technology that the company is using with Pfizer to develop a vaccine against Covid-19.
The function of mRNA vaccines is, in theory, very simple. What the compound does is give the immune system a description of the virus, thus showing which cells to fight.
BioNTech aims to deliver 10,000 personalized treatments to British patients by 2030. New research and development centers, including a laboratory in the city of Cambridge, are expected to help achieve the goal.
Vaccines are offered to patients with early stage and advanced stage cancer. Clinical trials are expected to begin in September this year.
According to Ugur Sahin, CEO of BioNTech, said, “This collaboration will cover many types of cancer and infectious diseases that collectively affect hundreds of millions of people worldwide.” oh The oncologist and immunologist says the company’s goal is to accelerate the development of immunotherapies and vaccines using technologies that have been researched for more than 20 years.
The institute worked on one of the most widely distributed vaccines during the pandemic, which taught scientists valuable lessons about collaboration with the National Health Service and about forecasting.
Henry Blackwell is a contributor at Mediarunsearch.co.uk, covering a wide range of topics including news, politics, business, technology, sport, entertainment, and lifestyle. He focuses on delivering clear, balanced reporting and useful information that helps readers stay informed about current events and emerging developments. His work highlights stories that matter to everyday audiences, with an emphasis on accuracy, relevance, and accessible journalism.